Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting
Broker reports that Poolbeg Pharma is quickly establishing itself as a specialist in rare diseases.
According to broker Shore Capital, Poolbeg Pharma PLC (AIM: POLB) is making significant progress toward becoming a rare disease company.
Poolbeg Pharma plc (AIM:POLB) Interim results for the six months to 30 June 2024
Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded
Poolbeg Pharma (AIM:POLB) to Present at the H.C. Wainwright 26th Annual Global Investment Conference
27 August 2024 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that
Poolbeg Pharma PLC – Voluntary Delisting from OTCQB Market
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is
Poolbeg Pharma PLC – Chief Executive Officer Jeremy Skillington PhD Talking To Zak Mir
Poolbeg Pharma Chief Executive Officer, Jeremy Skillington PhD present an overview of their current programmes and opportunities, focussing on POLB 001, data, exclusive option agreement and their AI-powered research using
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
9 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, confirms that the
Poolbeg Pharma PLC (AIM:POLB) Significant POLB 001 Patent Granted in USA
Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering
Poolbeg Pharma PLC (AIM:POLB) Option Agreement to Acquire Orphan Drug Candidate
Poolbeg Pharma PLC (AIM: POLB, OTCQB: POLBF) has secured an exclusive 12-month option agreement with Silk Road Therapeutics Inc to acquire a phase III-ready oral ulcer treatment for Behçet’s Disease.
Poolbeg Pharma PLC – Results for the year ended 31 December 2023
Significant pipeline advancements Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn Key senior management hires
Poolbeg Pharma PLC (AIM:POLB) POLB 001 US Patent Update
Notice of Allowance for Significant POLB 001 Patent in the United States Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio
Poolbeg Pharma PLC (AIM:POLB) Director/PDMR Shareholding
22 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received